Pharminent

Trump orders drafting of board to control NIH grant funding

President Donald Trump told White House OMB director Russell Vought to draft an executive order creating a board that would determine which grants the NIH funds, according to reports.

Kennedy names eight new members to USPSTF panel

HHS Secretary Robert F. Kennedy Jr. named eight new members to the U.S. Preventive Services Task Force this week, completing the 16-seat panel.

Beacon to file XLRP gene therapy after phase 3 win

Beacon is preparing to file for approval of its gene therapy for X-linked retinitis pigmentosa after reporting positive phase 3 data.

Alkermes’ orexin agonist shows ADHD potential in early trial

Alkermes said an orexin agonist therapy showed potential to treat people with ADHD in an early-stage study, which the company said is the first time an orexin agonist has done so.

Cue Biopharma’s hives drug hits phase 2 primary endpoint

A midstage study of Cue Biopharma’s chronic hives drug candidate met its primary endpoint, and the biotech plans to move the candidate into a phase 2b/3 trial.

Telix to acquire ITM in deal worth up to $2.35B

Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich in a transaction valued at up to $2.35 billion, including $1.65 billion upfront, combining Telix’s operations with ITM’s radioisotope production business and late-stage treatment candidate ITM-11.

Sandoz and mAbxience sign emicizumab biosimilar agreement

Sandoz and mAbxience have signed a licensing, development and commercialization agreement for a proposed emicizumab biosimilar candidate for haemophilia A.

Novo plans five or more blockbuster launches by 2030

Novo has laid out a plan to launch five or more blockbuster medicines between now and 2030, which it expects to grow annual revenues by around $23 billion.

Electra Therapeutics raises $350M in upsized IPO

Electra Therapeutics raised $350 million in an upsized IPO to support a potential first-in-class drug whose lead indication is a rare hyperinflammatory disorder with no FDA-approved treatments. Clinical-stage biotechs Marea Therapeutics and Sensorion also disclosed plans to enter the U.S. public markets.

TRex Bio and Retension Pharmaceuticals file IPO plans

Eli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals have each set out plans to go public this year.